|
|
||||||||
Ann Thorac Surg 1998;65:371-376
© 1998 The Society of Thoracic Surgeons
-Aminocaproic Acid for Primary Myocardial Revascularization
Department of Anesthesia, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada,
Department of Biostatistics, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada,
Department of Hematology, Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada
Accepted for publication July 16, 1997.
Dr Hardy, Montreal Heart Institute, 5000 Bélanger St, Montreal, PQ, Canada H1T 1C8 (e-mail: hardy@icm.umontreal.ca).
Background. The efficacy of prophylactic
-aminocaproic acid and tranexamic acid to reduce transfusions after primary myocardial revascularization was evaluated in a teaching hospital context.
Methods. Patients (n = 134) received either
-aminocaproic acid (15-g bolus + infusion of 1 g/h), high-dose tranexamic acid (10-g bolus + placebo infusion), or normal saline solution in a double-blind fashion. Anticoagulation and conduct of cardiopulmonary bypass were standardized.
Results. Tranexamic acid and
-aminocaproic acid produced a significant reduction in postoperative blood loss compared with placebo (median loss, 438 mL, 538 mL, and 700 mL, respectively). Transfusion of red cells was similar in all three groups. Nonetheless, the percentage of patients receiving hemostatic blood products was significantly decreased in the
-aminocaproic acid group compared with the placebo group (20% versus 43%; p = 0.03). Both tranexamic acid and
-aminocaproic acid significantly decreased total exposure to allogeneic blood products compared with placebo (p = 0.01 and p = 0.05, respectively), and this reduction was clinically important (median exposure, 2, 2, and 7.5 units, respectively). Fibrinolysis was inhibited significantly in both treatment groups.
Conclusions. We conclude that either high-dose tranexamic acid or
-aminocaproic acid effectively reduces transfusions in patients undergoing primary, elective myocardial revascularization.
This article has been cited by other articles:
![]() |
K. Ker, P. Edwards, P. Perel, H. Shakur, and I. Roberts Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis BMJ, May 17, 2012; 344(may17_1): e3054 - e3054. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Ngaage and J. M. Bland Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies Eur J Cardiothorac Surg, June 1, 2010; 37(6): 1375 - 1383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shander, D. Moskowitz, and T. S. Rijhwani The Safety and Efficacy of "Bloodless" Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63. [Abstract] [PDF] |
||||
![]() |
S. Thiagarajamurthy, A. Levine, and J. Dunning Does prophylactic tranexamic acid safely reduce bleeding without increasing thrombotic complications in patients undergoing cardiac surgery? Interact CardioVasc Thorac Surg, September 1, 2004; 3(3): 489 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zabeeda, B. Medalion, M. Sverdlov, S. Ezra, A. Schachner, T. Ezri, and A. J. Cohen Tranexamic acid reduces bleeding and the need for blood transfusion in primary myocardial revascularization Ann. Thorac. Surg., September 1, 2002; 74(3): 733 - 738. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Nzerue and B. Falana Refractory hyperkalaemia associated with use of epsilon-aminocaproic acid during coronary bypass in a dialysis patient Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1150 - 1151. [Full Text] [PDF] |
||||
![]() |
T. Miyashita, T. Kamibayashi, Y. Ohnishi, J. Kobayashi, and M. Kuro Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid therapy in primary cardiac valve surgery Perfusion, December 1, 2000; 15(6): 507 - 513. [Abstract] [PDF] |
||||
![]() |
M. Stafford-Smith, B. Phillips-Bute, D. N. Reddan, J. Black, and M. F. Newman The Association of {epsilon}-Aminocaproic Acid with Postoperative Decrease in Creatinine Clearance in 1502 Coronary Bypass Patients Anesth. Analg., October 1, 2000; 91(5): 1085 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chauhan, A. K. Bisoi, B. H. Rao, M. S. Rao, N. Saxena, and P. Venugopal Dosage of Epsilon-Aminocaproic Acid to Reduce Postoperative Blood Loss Asian Cardiovascular and Thoracic Annals, March 1, 2000; 8(1): 15 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Casati, D. Guzzon, M. Oppizzi, M. Cossolini, G. Torri, G. Calori, and O. Alfieri Hemostatic effects of aprotinin, tranexamic acid and {epsilon}-aminocaproic acid in primary cardiac surgery Ann. Thorac. Surg., December 1, 1999; 68(6): 2252 - 2256. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |